Eli Lilly, Novo Nordisk Stocks Rise. Only One Is Operating From a Position of Strength.
The obesity drug race is heating up in more ways than one.Eli Lilly, the world’s biggest pharmaceutical company by market value, benefited from some good news Friday.The Food and Drug Administration approved Lilly’s blockbuster drug for weight-loss Zepbound to also treat sleep apnea,
Novo Nordisk raises expectations for Eli Lilly after CagriSema slipup
Novo Nordisk (NVO) increased valuation gap with Eli Lilly (LLY) after its Phase 3 data for next-gen weight loss drug CagriSema disappointed. Read more here.
Novo Nordisk's dosing in CagriSema obesity drug trial puzzles investors
Novo Nordisk shareholders were seeking on Friday to find out why such a high number of patients in the late-stage trial of its next-generation obesity drug candidate CagriSema did not reach the highest dose strength of the medicine.
Novo Nordisk Stock Crashes on Obesity Drug Data. It’s a Win for Eli Lilly.
Novo Crashes After Obesity Drug Misses Lofty Expectations. Lilly, Viking And Amgen Surge.
Novo Nordisk stock crashed Friday after the firm's next-generation weight-loss drug missed expectations in a highly anticipated study.
Novo Nordisk shares plunge after CagriSema obesity drug trial disappoints
Novo Nordisk said on Friday its experimental next-generation obesity drug CagriSema helped patients cut their weight by 22.7% in a late-stage trial, below the 25% it had expected, wiping as much as $125 billion off its market value.
Novo Nordisk Dives On CagriSegma Obesity Drug Trial. Eli Lilly, Viking Jump.
Novo Nordisk stock crashed Friday after the Danish giant reported its experimental obesity drug CagriSegma missed goals. Eli Lilly and Viking Therapeutics jumped
Eli Lilly & Co. stock underperforms Tuesday when compared to competitors
Shares of Eli Lilly & Co. LLY sank 0.08% to $795.67 Tuesday, on what proved to be an all-around favorable trading session for ...
Does This News From the FDA Make Eli Lilly a Buy for 2025?
Eli Lilly (NYSE: LLY) soared more than 60% from the start of the year through its peak this summer, thanks to the company's ...
Eli Lilly Stock Is Rising Monday: What's Going On?
Eli Lilly and Company (NYSE: LLY) shares are trading higher Monday. The upward momentum in the stock comes after the FDA ...
The FDA just approved Eli Lilly's Zepbound for sleep apnea — and Medicare coverage could be next
Eli Lilly (LLY) announced today that its blockbuster weight-loss drug Zepbound was approved by the U.S. Food and Drug ...
This Is Huge News for Eli Lilly Investors
Eli Lilly just gave investors several reasons to cheer.
Is Now a Good Time to Buy the Dip in Eli Lilly Stock?
Since pharmaceutical giant Eli Lilly (NYSE: LLY) reported earnings for the third quarter on Oct. 30, shares have been ...
Eli Lilly, Qualcomm, Rumble: Market Minute
Yahoo Finance host Akiko Fujita highlights three of the top trending stocks and stories as part of today's Market Minute.
Eli Lilly Is Putting Dividend Growth Stocks to Shame With Yet Another Huge Increase to Its Payout
What Eli Lilly ( LLY -0.05%) is doing is far more impressive. The company has been increasing its dividend at a high rate, ...
Zepbound helps shed more weight than Wegovy, Eli Lilly study says
A new study put Eli Lilly's Zepbound and Novo Nordisk's Wegovy to the test. Here's which one will help you lose more weight.